Symptomatic cerebral oedema during treatment of diabetic ketoacidosis: effect of adjuvant octreotide infusion by Seewi, Ora et al.
CASE REPORT Open Access
Symptomatic cerebral oedema during treatment
of diabetic ketoacidosis: effect of adjuvant
octreotide infusion
Ora Seewi
*, Anne Vierzig, Bernhard Roth, Eckhard Schönau
Abstract
Introduction: A potentially lethal complication of diabetic ketoacidosis (DKA) in children is brain oedema, whether
caused by DKA itself or by the therapeutic infusion of insulin and fluids.
Case presentation: A 10-year old previously healthy boy with DKA became unconscious and apnoeic due to
cerebral oedema (confirmed by abnormal EEG and CT-scan) during treatment with intravenous fluids (36 ml/h) and
insulin (0.1 units/kg/h). He was intubated and artificially ventilated, without impact on EEG and CT-scan.
Subsequently, adjuvant infusion of octreotide was applied (3.5 μg/kg/h), suppressing growth hormone (GH) and
IGF-1 production and necessitating the insulin dose to be reduced to 0.05 - 0.025 units/kg/h. The brain oedema
improved and the boy made a full recovery.
Conclusion: Co-therapy with octreotide was associated with a favourable outcome in the present patient with
DKA and cerebral oedema. Whether this could be ascribed to the effects of octreotide on the insulin requirement
or on the GH/IGF-axis remains to be elucidated.
Introduction
Cerebral oedema is the most feared complication of
DKA. The pathogenesis appears complex and is poorly
understood [1]. According to a recent working hypoth-
esis, dehydration and hypocapnia diminish cerebral per-
fusion, resulting in mild brain ischaemia and subsequent
cytotoxic and vasogenic cerebral oedema [1]. In this con-
text, hypoxia-induced VEGF activity may play a role [2].
Insulin treatment might also contribute, for example via
its sodium-retaining effects, or by its effects on the
growth hormone (GH)/insulin-like growth factor (IGF)-
axis [3]. Insulin increases serum IGF-1 and decreases
IGFBP-1, thereby increasing free IGF-1 activity. IGF-1
increases capillary permeability [4] and oedema forma-
tion [5,6], probably via increasing the activity of VEGF
[7,8]. As insulin enters the brain [9], these effects may -
on a local level-contribute to cerebral oedema during
DKA. Somatostatin, which counteracts some insulin
effects on the GH/IGF-axis [10] and lowers free IGF-1 in
particular [11], was successfully applied in complicated
DKA by Bosnak et al. [12]. These authors added a soma-
tostatin infusion to the standard DKA therapy in two
unconscious children with DKA who subsequently
regained consciousness within 3-4 hours. The therapeutic
mechanism of somatostatin in this condition remains
obscure. We provide additional evidence for the use of
somatostatin to improve the outcome of cerebral oedema
in childhood DKA.
Case presentation
A previously healthy boy of 10 years (estimated body
weight 25 kg) was admitted acutely after vomiting for
8 hours, preceded by polyuria, polydipsia, weight loss
and malaise for 3 days. He was conscious, but drowsy
(Glasgow Coma Scale score 12). A diagnosis of diabetic
ketoacidosis was made because of hyperglycaemia
(1329 mg/dl) and metabolic acidosis (pH 7.07, base
excess-19.7 mmol/l). He was severely dehydrated and
displayed Kussmaul breathing. Immediately upon admis-
sion he received a s.c. injection of 2.5 units of regular
human insulin, followed by continuous intravenous infu-
sion of regular insulin at a dose of 0.1 U/kg/h. Simulta-
neously, an intravenous bolus infusion of 250 ml of
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intravenous infusion of 0.9% saline and 0.45% NaCl plus
5 %g l u c o s e( 3 6m l / h ) .T h eb a s e l i n eb l o o dc h e m i s t r y
showed pre-renal kidney failure (serum creatinine 3.75
mg/dl, urea 151 mg/dl, uric acid 20.4 mg/dl), circulatory
insufficiency (lactate 3.2 mmol/l) and dehydration (mea-
sured osmolality 444 mosmol/kg, haematocrit 54%).
Furthermore, leukocytosis (15.77× 10-9/l) and a reduced
serum chloride of 88 mmol/l were noted. The serum
sodium, potassium, phosphat e ,c a l c i u m ,m a g n e s i u m ,
CRP, liver enzymes and clotting factors were normal.
The serum GH was elevated (7.5 ng/ml), while the IGF-
1 was below the detection limit (< 10 ng/ml), consistent
with acquired GH insensitivity. After 10 hours of treat-
ment with insulin and potassium-supplemented fluids,
the acidosis had almost been cured (pH 7.39, base
excess -2.8 mmol/l), and glycaemia was more than
halved (549 mg/dl). The serum osmolality had dropped
to 380 mosmol/l, the GH had fallen to 2 ng/ml, and the
IGF-1 had risen to 23 ng/ml (suggestive of an immedi-
ate, insulin-induced rise in circulating IGF-1 [13,14]).
See Table 1 for a summary of the laboratory data.
However, the boy became agitated and febrile and
exhibited apnoeic phases indicative of incipient cerebral
oedema. He was intubated and artificially ventilated
under sedation with propofol and later midazolam, keta-
min and fentanyl. Repeated CT-scans of the brain were
unhelpful (in retrospect, the intercaudate diameter was
narrowed by 4.8 mm (see Fig 1a)). Electroencephalogra-
phy (EEG), however, showed a slow basic rhythm con-
sistent with the manifestation of encephalopathy. At this
point, DKA treatment failure was considered and it was,
therefore, decided to try infusion of the somatostatin-
analogue octreotide (3.5 μg/kg/h), according to Bosnak
et al. [12]. In response to the octreotide infusion, the
insulin requirement decreased while serum GH and
IGF-1 decreased below the detection limits, and serum
osmolality decreased to 342 mosmol/l. After 20 hours of
co-therapy with octreotide, extubation was successfully
attempted. The octreotide infusion was tapered off and
Table 1 Laboratory data before, during and after
treatment of DKA
Blood chemistry Time (h) after admission
01 0 2 44 4
Glucose (mg/dl) 1392 549 214 114
PH 7.07 7.39 7.33 7.35
HCO3 (mmol/l) 9.2 22.5 20.3 21.7
Base excess (mmol/l) -19.7 -2.8 -4.9 -3.1
Na+ (mmol/l) 143 162 154 158
K+ (mmol/l) 5.8 4.9 5.6 3.5
Osmolality (mosmol/kg) 444 380 n.a* 342
Creatinine (mg/dl) 3.75 1.86 1.66 1.24
Haematocrit (%) 54 45 44 40
Lactate (mmol/l) 3.2 1.5 1.3 1.1
GH (ng/ml) 7.5 n.a* 2.0 < 0.16
IGF-1 (ng/ml) < 10 n.a* 23 < 10
*not analysed
Reference values for a 10 year old male child
Fasting blood glucose: 60-110 mg/dl;
arterial pH 7.4;
arterial HCO3 31 mmol/l;
arterial base excess +5 mmol/l;
arterial serum lactate 1.0-1.6 mmol/l;
venous serum natrium 130-145 mmol/l;
venous serum potassium 3.2-5.4 mmol/l;
venous serum osmolality 280-296 mosmol/kg;
venous serum creatinine < 0.9 mg/dl;
venous blood haematocrit 34-46%;
venous serum random GH < 4 ng/ml;
venous serum IGF-1: 159-300 ng/ml.
Figure 1 Intercaudate diameter: (a) according to Glaser et al.
[15], during DKA. Computed tomography without contrast media;
(b) after full recovery from DKA. Magnetic resonance imaging (T1
weighted) without contrast media.
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tions. The patient made a full recovery without neurolo-
gical deficits. The treatment is summarized in Table 2.
The transient increases in liver enzymes had normal-
ized at the time of discharge, as had all of the other
laboratory abnormalities, except for an HbA1c of 12%
(normal 4-6%). The fasting serum GH was 0.16 ng/ml
and the IGF-1 was 132 ng/ml, suggesting normalized
GH sensitivity. The patient was discharged with 23 U of
NPH, and 20 U of regular human insulin per day. One
week after discharge, the intercaudate diameter was no
longer narrowed on cranial MRI (Fig. 1b).
Discussion
The case of our patient is comparable to those reported
by Bosnak et al. [12], in that a comatose child with
DKA receiving co-therapy with the somatostatin analo-
gue octreotide regained consciousness. However, the
patients of Bosnak et al. were already unconscious
before the onset of treatment, and it was claimed that
they did not have brain oedema [12]. By contrast, our
patient lost consciousness during insulin and fluid sub-
stitution and subsequently developed cerebral oedema
(according to the established criteria [15], see Fig. 1a, b).
Fluid overload, the use of sodium bicarbonate or pro-
longed acidosis are unlikely to have caused cerebral
oedema in our patient as sodium bicarbonate administra-
tion had been withheld and the net fluid gain was only
326 ml (13 ml/kg) during the first 10 hours, and the
acidosis was almost cured when cerebral oedema
occurred. However, hyperosmolality had dropped consid-
erably (from 444 to 380 mosmol/l) at that time point,
probably because 0.6% rather than 0.9% saline was given
without consideration of the current guidelines [15,16].
This might have contributed to the development of brain
oedema, although consciousness was regained later
despite a further drop in osmolality (from 380 to 342
mosmol/l). Thus, additional factors deserve considera-
tion, for example insulin [17] and its effects on IGF-1.
In insulin-naive untreated type-1 diabetic children
with DKA, serum insulin concentrations are < 5 μU/ml
(unpublished observation) and increase upon therapeutic
intravenous insulin infusion at a rate of 0.1 U/kg/h to
approximately 60 - 100 μU/ml [13,18-20]. Such serum
insulin levels could also have been assumed in our
patient at the time of developing brain oedema (unfortu-
nately the insulin levels were not measured). Continuous
hyperinsulinaemia such as this overcomes insulin resis-
tance, shuts off glycolysis, gluconeogenesis and ketogen-
esis, half-maximally increases glucose uptake[20], and
furthermore substantially increases circulating IGF-1
within a few hours [13,14]. A rapid increase in circulat-
ing IGF-1 from below the normal range to the upper
normal range [13,14] may contribute to the formation
of oedema in general, and to cerebral oedema during
DKA treatment, which is consistent with previous
reports [4-6].
During co-therapy with octreotide, the insulin infusion
rate had to be reduced from 0.1 U/kg/h to 0.05 U/kg/h
(as with the patients of Bosnak et al.), probably due to
the inhibition of glucagon and GH secretions. An insu-
lin infusion rate this low is associated with a serum
insulin concentration of 10-15 μU/ml, and avoidance of
the immediate upregulation of serum IGF-1 during
DKA treatment (unpublished observation). Contrary to
current guidelines [16,21] it was recently shown that
l o wr a t ei n s u l i ni n f u s i o nm a yb ep a r t i c u l a r l ys a f ei n
DKA [17,22].
In our patient, octreotide completely inhibited the
insulin-induced surge of circulating IGF-1, most likely
through the inhibition of GH secretion. Moreover,
octreotide must have affected the serum IGFBP-1 and
free IGF-1 in our patient (not measured). In severe insu-
lin deficiency, for example in diabetic ketoacidosis,
IGFBP-1 is upregulated while hepatic IGF-1 secretion is
reduced, despite increased GH [2,13,14,23]. Insulin sub-
stitution reverses these abnormalities [2]. By contrast,
octreotide administration increases circulating IGFBP-1
[10,11] and thereby reduces free IGF-1 [11]; moreover,
it antagonizes the stimulating effect of GH on IGF-1
generation in various tissues, e.g. the brain. Both pro-
cesses may have contributed to the resolution of cere-
bral oedema in our patient, and to the regaining of
consciousness in the patients of Bosnak et al., as resolu-
tion of diabetic macula oedema was observed in
response to octreotide administration [24,25].
In summary, we report for the first time a successful
adjunctive therapy with octreotide in a patient with DKA
and proven cerebral oedema. Although we cannot prove
a cause-effect relationship, we believe that the potential
of octreotide in this condition warrants further study.
Abbreviations
CT: computed tomography; DKA: diabetic ketoacidosis; GH: growth
hormone; IGF-1: insulin-like growth factor 1; IGFBP-1: insulin-like growth
Table 2 Treatment items before, during and after
treatment of DKA
Treatment items Time (h) after admission
01 0 2 4 4 4
net fluid gain* (ml/kg) 10 13 83 116
GCS**score (3-15) 12 8 not applicable 15
Artificial ventilation
-/+
—– < ++++ ++++++++++ ++++ > —
Octreotide infusion
(μg/kg/h)
0 0 3.5 1.8
Insulin infusion
(U/kg/h)
0.1 0.1 0.05 0.025
*total intravenous fluids minus urinary output; **GCS = Glasgow Coma Scale
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Page 3 of 4factor binding protein 1; MRI: magnetic resonance imaging; VEGF: vascular
endothelial growth factor
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